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Abstract 
We describe two Finnish siblings in whom an incidentally detected elevated creatine kinase 
activity eventually led to a diagnosis of limb-girdle muscular dystrophy-dystroglycanopathy 
(Type C12; MDDGC12). When diagnosed at age 10 and 13 years, they were mildly affected 
with a slow or non-progressive disease course. The main symptoms comprised infrequent hip 
cramps triggered by flexion, neck cramps triggered by yawning, transient growing pains, calf 
hypertrophy and mild proximal muscle weakness. Their cognitive and motor developments 
were unremarkable and they were physically active. Whole-exome sequencing revealed 
compound heterozygous mutations, both of which were novel, in the protein O-mannosyl 
kinase (POMK) gene in both siblings; a missense mutation, p.Pro322Leu (c.965C>T), and a 
nonsense mutation, p.Arg46Ter (c.136C>T). The results were confirmed by Sanger 
sequencing, showing that the parents were heterozygous carriers of one mutation each. This 
report adds to the literature by providing phenotype and genotype data on this ultra-rare 
POMK-related dystroglycanopathy.  
 
 
 
 
 
 
 
 
Manuscript 
 
4 
 
1. Introduction 
Dystroglycanopathies are a group of muscular dystrophies characterised by considerable 
clinical and genetic heterogeneity. They are caused by disruption in the interactions between 
the transmembrane protein dystroglycan and extracellular matrix components. These 
interactions are necessary for normal muscle and brain development [1]. In these interactions, 
glycosylation plays a crucial role. Most known dystroglycanopathy mutations are located in 
genes related to the glycosylation process rather than in the dystroglycan gene itself [1].  
The POMK gene (MIM 615247), located on chromosome 8p11, encodes the protein O-mannose 
kinase which is necessary for proper glycosylation and function of the dystroglycan complex 
[2]. Biallelic mutations in the POMK gene cause limb-girdle muscular dystrophy-
dystroglycanopathy (type C12; MDDGC12) (MIM 616094). To our knowledge, two such 
families have been described; one in which two Jordanian sibs presented with limb-girdle 
muscular dystrophy (LGMD) and cognitive impairment, and another in which a child born to 
consanguineous parents presented with LGMD, mild learning difficulties and congenital mirror 
movements [1,3]. POMK mutations can also cause the more severe Walker-Warburg syndrome 
(Muscular dystrophy-dystroglycanopathy, congenital with brain and eye anomalies, type A12; 
MDDGA12) (MIM 615249), encompassing brain and eye abnormalities in addition to the 
muscular dystrophy. To our knowledge, three such families have been described in previous 
reports [1,2,4]. Due to the small number of cases described, little is known about the range of 
clinical variability of disorders caused by POMK mutations. 
We report clinical, molecular, histological, neurophysiological and imaging data on a sib pair 
with limb-girdle muscular dystrophy-dystroglycanopathy type C12, caused by a novel 
compound heterozygous mutation in the POMK gene. The incidental finding of an elevated 
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serum creatine kinase (CK) activity in the probands in infancy, which eventually led to the 
diagnosis, allowed for observation of the onset and the progression of the disease. 
 
2. Case Report 
2.1 Clinical phenotype 
The probands comprise a Finnish sib pair born to non-consanguineous parents. The older 
sister was born at term with birth asphyxia due to placental abruption. She suffered a mild 
asphyxia-related kidney injury for which she was on follow-up. At 6 years of age, while being 
investigated for elevated liver enzymes, she presented with elevated CK values of 1000-4000 
U/L. Her motor and cognitive development as well as her growth were normal. She started 
walking at age 15 months. Her visual acuity was normal. She had unilateral high-frequency 
hearing loss (hearing threshold 65 decibel at 6000 and 8000 Hertz). In childhood she suffered 
from transient growing pains. Since school age she has experienced infrequent hip cramps 
triggered by hip flexion when doing for instance sit-ups, and by cramps in the neck region 
triggered by yawning. She has, at times, suffered from exercise-induced knee ache. Testing of 
muscle strength at 10 years of age using myometry showed muscle power slightly below 
average for hip adductors and abductors, as well as for knee extensors and ankle plantar 
flexors, as compared with normative values. On the contrary, muscle power in other arm and 
leg muscle groups were equal to or even stronger than average [5]. Subsequent evaluations 
showed muscle strength within normal limits.  
Her electromyography (EMG) findings were normal, however, only one muscle (right 
gastrocnemius) was examined due to her fear of needles. Neurography of the median, tibial 
peroneal and sural nerves gave normal results. A muscle biopsy at 7 years of age was 
paraffin-embedded and showed normal findings. Echocardiography (followed up every two 
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years starting from 7 years of age, with the latest evaluation done at 14 years of age) and 
spirometry showed no signs of cardiac or respiratory involvement. Magnetic resonance 
imaging (MRI; 1,5 Tesla scanner) with T1-weighted and STIR images of muscles in 
shoulders, upper arms, thighs and pelvic region was normal, without signs of fatty 
replacement or edema (not shown).  
 
The younger brother was born preterm by caesarean section due to placenta praevia. His 
motor and cognitive development as well as his growth were unremarkable. He started 
walking at age 13 months. He had normal hearing and visual acuity. As a consequence of his 
sister´s incidentally detected CK elevation, his CK level was determined, showing markedly 
increased levels of up to 7000 U/L. In childhood, he suffered from transient nocturnal 
growing pains. He also suffered from thigh stiffness and infrequent pain and cramps in the 
thighs and groins triggered by hip flexion. Like his sister, he experienced infrequent neck 
region cramps triggered by yawning. Muscle strength in his hip abductors and adductors as 
well as upper limbs was slightly weak, making it, at times, difficult for him to do sit-ups and 
arm push-ups. 
His EMG was normal (neurography of tibial, peroneal and sural nerve, as well as myography 
of vastus lateralis, tibialis anterior and biceps). A muscle biopsy taken from the vastus 
lateralis muscle at age 6 showed moderate chronic myopathic changes, small groups of 
regenerating fibres, sparse inflammatory cell infiltrates, α-dystroglycan deficiency in a 
majority of fibres with preserved expression in single, scattered fibres and normal merosin 
immunolabelling (Figure 1). The major histocompatibility complex 1 (MHC1) protein was 
slightly up-regulated (not shown). Electrocardiography (ECG) showed isolated persistent 
deep Q-waves in leads V5-6 from the age of 5 years onwards. At the age of 7 years, the boy 
had a history of syncope of unknown etiology (electroencephalography, echocardiography 
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and 24-hour ECG were normal). Echocardiography was normal at initial evaluation at the age 
of 5 years but gradually turned pathological after the age of 8 years, revealing mild 
enlargement and borderline weakened function of the left ventricle by the age of 12 years. No 
cardiac MRI was done. The boy is on regular cardiac follow-up (echocardiography and 24-
hour ECG) every 6-24 months and receives no treatment. There were no signs of respiratory 
involvement. MRI findings (1,5 Tesla, T1-weighted and STIR images) in the muscles of the 
shoulder region, upper arms, thighs and pelvic region were within normal limits, without 
signs of fatty replacement, although with minimal high signal changes in the right shoulder 
and left pelvic and thigh regions (not shown).  
On clinical examination at age 13 and 10 years respectively, both the sister and brother had 
calf hypertrophy (Figure 2), mild lumbar lordosis and slightly winged scapulae, brisk tendon 
reflexes (interpreted as normal) in the lower extremities, weakened but positive tendon 
reflexes in the upper extremities, absent Babinski signs and negative Gowers´ signs. They had 
no mirror movements, which have been related to POMK mutations in a previous report [3]. 
The brother had difficulty in walking on heels. Both sibs were physically active and 
considered themselves symptom-free and as physically fit as their peers. Brain MRI was not 
performed. 
Family history of muscle disease was non-contributory, and the parents´ CK levels were 
normal. 
 
2.3 Molecular findings 
The patients were enrolled into the MYO-SEQ project (myo-seq.org), an international 
research collaboration that applies whole exome sequencing (WES) to patients with 
undiagnosed limb-girdle muscle weakness. At least 250 ng of DNA (>2 ng/µl) for each 
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sibling was used as a template for WES. The resulting data were processed by the Genomics 
Platform at the Broad Institute of Harvard and MIT (Boston, MA, USA) as described 
previously [6]. The variant call set was uploaded onto the Broad Institute of Harvard and 
MIT’s seqr platform (https://www.seqr.broadinstitute.org) and POMK was analysed for 
biologically relevant variants previously described by Johnson et al. [7].  
Both siblings were shown to harbour two rare variants in POMK. The first was a stop-gained 
nonsense mutation, p.Arg46Ter (hg19 chr8:42958827, c.136C>T), and the second was a 
missense mutation, p.Pro322Leu (hg19 chr8:42977932, c.965C>T). Both variants are very 
rare in the control population (minor allele frequency [MAF] <0.0001) and have never been 
found in homozygosis. Sanger sequencing confirmed the presence of the variants in trans in 
the siblings. Each unaffected parent was only heterozygous for one of the variants each. We 
have submitted the variants and phenotype descriptions to a public database; the Leiden Open 
Variant Database (https://www.LOVD.nl). 
 
 
3. Discussion 
The POMK gene (synonym SGK196) encodes a 350 amino acid protein comprising 5 exons 
[4]. The full-length wild-type POMK protein has a predicted molecular weight of 40.15 kDa. 
The gene is conserved in mammals and amphibians [2]. Supporting the presumption that 
POMK mutations cause muscle disease, Di Costanzo and colleagues observed high expression 
of POMK in muscle and brain tissues during fetal development, especially during myocyte 
differentiation. In zebrafish embryos, knockdown of POMK led to muscular dystrophy, 
stressing the importance of POMK for early muscle development [1]. Moreover, protein 
analysis studies by von Renesse et al. showed an absence of POMK protein expression in 
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fibroblasts and muscle cells derived from patients with homozygous truncating POMK 
mutations, whereas such expression was present in controls [2]. 
The novel mutations in our patients comprised one nonsense mutation (p.Arg46Ter) in exon 
4, resulting in a premature termination of the amino acid sequence, and a missense mutation 
(p.Pro322Leu) in exon 5. High Combined Annotation-Dependent Depletion (CADD) scores 
of 35 and 27.7 respectively, suggest both variants are damaging to the protein [8]. 
Interestingly, all cases with POMK-related dystroglycanopathies reported to date have at least 
one mutation in exon 5 [1-4]. Despite the lack of functional studies of the specific mutations 
identified in our patients, the phenotype, consistent with LGMD, the elevated CK activity as 
well as the α-dystroglycan deficiency in the muscle biopsy of the brother strongly argues for 
pathogenicity of the mutations. We interpret the slight up-regulation of MHC 1 as unspecific 
and compatible with the occurrence of occasional inflammatory infiltrates sometimes seen in 
muscle biopsies of patients with muscular dystrophy. Hence, the current report supports 
previous studies claiming a causative role of POMK mutations in dystroglycanopathies. 
 
POMK-related dystroglycanopathies are ultra-rare autosomal recessive disorders. To our 
knowledge, when taking into account the current study, there are, to date, nine published 
cases from six different families [1-4]. As with dystroglycanopathies in general, their 
phenotypic presentations vary widely. On comparison with the published cases, we were 
unable to pinpoint any clear-cut genotype-phenotype correlation. Whether this lack of 
correlation is explained by chance due to the small sample, or by a factual lack of correlation, 
remains to be seen as new cases are identified in the future. Our two patients, who had a 
childhood onset of mild LGMD with normal cognition, represent the least severe phenotype 
among the published POMK cases. The mild cardiac involvement observed in the boy, 
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however, has not been reported previously and may either represent a new phenotypic feature 
of POMK-related dystroglycanopathies or be unrelated to it. The two Jordanian sibs with 
MDDGC12 had a clinical presentation of infancy-onset, fairly slowly progressive LGMD 
with cognitive deficit, caused by a severe protein-truncating homozygous missense mutation 
in POMK [1]. Interestingly, the same allelic variant was identified in a more severely affected 
Lebanese sib pair diagnosed with MDDGA12, who had infancy-onset muscle weakness and 
hypotonia, developmental delay, wheel-chair dependency, affected vision and brain MRI 
abnormalities - again illustrating the wide phenotypic variation [2]. Furthermore, the 
adolescent boy reported by Ardicli et al. had childhood-onset slowly progressive LGMD with 
congenital mirror movements and brain abnormalities on MRI, caused by a homozygous 
missense mutation in POMK [3].Finally, an Italian boy diagnosed with MDDGA12 had a 
severe infancy-onset phenotype of hypotonia, cognitive impairment, epilepsy, and brain and 
eye abnormalities. He deceased at the age of 4 years, and had a compound heterozygous 
POMK mutation; one frameshift mutation causing a premature termination and another 
mutation causing the substitution of a highly conserved amino acid in exon 5 [1].  
 
In summary, we report novel compound heterozygous POMK mutations in two siblings with a 
childhood onset LGMD, who are mildly affected with a slow or non-progressive disease 
course. They were cognitively unaffected and seemed to have isolated muscle affection, 
however, the cardiac pathology in the brother may constitute a new phenotypic feature of 
MDDGA12C. This report adds to the literature by providing new phenotypic data on this 
ultra-rare disease. As with rare diseases in general, further case reports are needed to elucidate 
the entire phenotypic spectrum of POMK- related dystroglycanopathies. 
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